Welcome to our dedicated page for Greenwich LifeSciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich LifeSciences stock.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a clinical-stage biopharmaceutical company dedicated to the development of groundbreaking immunotherapies aimed at preventing breast cancer recurrences. The company's flagship product, GP2, is an immunotherapy designed to stimulate the body's immune system to target and eliminate HER2/neu-expressing cancer cells, particularly in patients who have already undergone surgery for breast cancer.
GP2 leverages the HER2/neu transmembrane peptide to elicit a targeted immune response, providing a promising approach to cancer treatment. Another significant component of their pipeline is the GM-CSF Immunoadjuvant, which has shown potential in enhancing monocyte and neutrophil cytotoxicity against melanoma tumor cells, as well as boosting activity-dependent cellular cytotoxicity against targets coated with anti-ganglioside antibodies.
The company’s ongoing clinical trials are a testament to its commitment to innovation and excellence in cancer treatment. These trials are being conducted in collaboration with a steering committee comprising esteemed members from various medical institutions, ensuring rigorous oversight and adherence to the highest standards of clinical research.
Greenwich LifeSciences places a strong emphasis on advancing cancer immunotherapy to selectively stimulate an individual's immune system to attack cancer cells, thereby inhibiting the spread of the disease. Their work not only focuses on breast cancer but extends to other cancer types, showcasing a broad potential for impact in oncology.
With a robust pipeline, strategic partnerships, and a clear focus on unmet medical needs, Greenwich LifeSciences is poised to be a leader in the biopharmaceutical industry. Investors and stakeholders can stay updated on the latest developments and company performance through regular news updates and reports.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that its underwriter has purchased an additional 70,000 shares at $40.00 each in a public offering, bringing total gross proceeds to approximately $29.2 million. The offering was facilitated by Aegis Capital Corp. The SEC declared the registration statement for the shares effective on December 17, 2020. Greenwich LifeSciences is focused on developing GP2, an immunotherapy for preventing breast cancer recurrences, with a Phase III trial planned following a successful Phase IIb trial with promising results.
Greenwich LifeSciences (Nasdaq: GLSI) announced an exclusive interview with CEO Snehal Patel on The RedChip Money Report, airing on Bloomberg International. Patel highlights GP2's development, an immunotherapy targeting breast cancer recurrence, which showcased 0% recurrences in a Phase IIb trial after 5 years. The interview covers planned Phase III trials and key milestones. Greenwich LifeSciences aims to combat invasive breast cancer, with GP2 demonstrating tolerance in 138 patients across trials.
Greenwich LifeSciences (Nasdaq: GLSI) announced CEO Snehal Patel's participation in upcoming virtual investor conferences. The conferences will highlight GP2 trial data aimed at preventing breast cancer recurrences. Key events include: B. Riley Securities Oncology Investor Conference on January 21, 2021, and the BIO CEO & Investor Conference from February 16-18, 2021, featuring networking opportunities with investors. GP2 shows promising Phase IIb results, with no recurrences in 3+ HER2 patients after 5 years. Visit greenwichlifesciences.com for more details.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that its CEO, Snehal Patel, will participate in three virtual investor conferences during the week of January 11, 2021. These include the H.C. Wainwright BioConnect Conference with an on-demand presentation starting at 6:00 am EST, the Biotech Showcase 2021, and the BIO Partnering event at the 2021 JP Morgan Healthcare Conference. The company’s GP2 immunotherapy aims to prevent breast cancer recurrences in patients post-surgery, showing promising Phase IIb trial results with no recurrences in a specific patient group after five years.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that the replay of its December 15, 2020 presentation at the LD Micro Main Event is now available. CEO Snehal Patel highlighted the successful Phase IIb trial of GP2, which showed a remarkable 100% disease-free survival rate in HER2 positive patients over five years. The company plans to initiate a Phase III trial to further investigate GP2 as an immunotherapy for preventing breast cancer recurrences. For further details, the replay can be accessed through their website.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) will ring the Nasdaq opening bell on December 28, 2020, to celebrate its IPO completion. CEO Snehal Patel and the team will participate in a virtual ceremony starting at 9:20 am EST. The company has raised over $33 million to fund its GP2 immunotherapy aimed at preventing breast cancer recurrences. The Phase III clinical trial is set to commence, following positive results from a Phase IIb trial where no recurrences were observed in the HER2/neu 3+ adjuvant setting. This initiative aims to improve outcomes for breast cancer survivors.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has announced the closing of its underwritten public offering, yielding gross proceeds of $26.4 million. The funds will be allocated towards manufacturing and clinical trial completions for the GP2 Phase III trial, Biologics Licensing Application submission to the FDA, and development of additional products, including a coronavirus vaccine. An additional 99,000 shares may be purchased by underwriters to increase total proceeds to approximately $30.4 million.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced an upsized public offering, expected to raise approximately $26.4 million. The offering includes 660,000 shares priced at $40.00 per share, with a potential increase to $30.4 million if underwriters exercise their option for an additional 99,000 shares. Proceeds will fund clinical trials, completion of manufacturing, and support for a coronavirus vaccine program. The offering is set to close around December 22, 2020.
Greenwich LifeSciences (Nasdaq: GLSI) has announced an option agreement with Westport Bio to in-license a pre-clinical coronavirus vaccine program currently in animal testing. The agreement involves up to $250,000 in research sponsorship, plus additional fees. Westport Bio's vaccine candidates aim to enhance existing DNA/RNA vaccines. CEO Snehal Patel highlighted their aim to achieve greater protection against COVID-19, leveraging previous success with a pneumonic plague vaccine that provided 100% protection. The company remains focused on its GP2 breast cancer immunotherapy while exploring new candidates.
Greenwich LifeSciences announced the publication of a second poster for its GP2 Phase III clinical trial targeting breast cancer recurrence at the San Antonio Breast Cancer Symposium. The trial seeks to replicate previous results showing no recurrences in HER2/neu 3+ patients after treatment with GP2 + GM-CSF. The Phase III trial will include interim analysis for FDA marketing approval and involve 11 injections over three years. CEO Snehal Patel expressed confidence in the collaboration with Baylor College of Medicine to achieve these goals.
FAQ
What is the current stock price of Greenwich LifeSciences (GLSI)?
What is the market cap of Greenwich LifeSciences (GLSI)?
What is Greenwich LifeSciences, Inc.?
What is GP2?
What does the GM-CSF Immunoadjuvant do?
What types of cancer is Greenwich LifeSciences targeting?
Who oversees the clinical trials at Greenwich LifeSciences?
What is the significance of HER2/neu in cancer treatment?
Are there any ongoing clinical trials?
How can investors stay updated on the company?
What makes Greenwich LifeSciences' approach unique?
Where can I find more information about Greenwich LifeSciences?
